Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other Non-Current Liabilities (2017 - 2023)

Denali Therapeutics (DNLI) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $379000.0 as the latest value for Q3 2023.

  • Quarterly Other Non-Current Liabilities changed 0.0% to $379000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $379000.0 through Sep 2023, changed 0.0% year-over-year, with the annual reading at $379000.0 for FY2022, 0.0% changed from the prior year.
  • Other Non-Current Liabilities for Q3 2023 was $379000.0 at Denali Therapeutics, roughly flat from $379000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $701000.0 in Q4 2020, with the low at $379000.0 in Q4 2019.
  • Average Other Non-Current Liabilities over 5 years is $451894.7, with a median of $379000.0 recorded in 2019.
  • The sharpest move saw Other Non-Current Liabilities surged 211.29% in 2019, then tumbled 45.93% in 2021.
  • Over 5 years, Other Non-Current Liabilities stood at $379000.0 in 2019, then soared by 84.96% to $701000.0 in 2020, then crashed by 45.93% to $379000.0 in 2021, then changed by 0.0% to $379000.0 in 2022, then changed by 0.0% to $379000.0 in 2023.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $379000.0, $379000.0, and $379000.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.